Masimo (MASI) Set to Announce Earnings on Tuesday

Masimo (NASDAQ:MASI) is scheduled to be announcing its earnings results after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of $0.71 per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Tuesday, February 27th. The medical equipment provider reported $1.25 EPS for the quarter, topping analysts’ consensus estimates of $0.82 by $0.43. The firm had revenue of $548.90 million for the quarter, compared to analysts’ expectations of $545.69 million. Masimo had a net margin of 3.98% and a return on equity of 13.77%. The business’s revenue for the quarter was down 11.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.32 earnings per share. On average, analysts expect Masimo to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Masimo Price Performance

Masimo stock opened at $137.00 on Friday. The stock has a market cap of $7.25 billion, a price-to-earnings ratio of 90.73 and a beta of 0.99. The firm has a 50-day moving average of $136.10 and a two-hundred day moving average of $118.52. Masimo has a 1 year low of $75.22 and a 1 year high of $188.76. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.18 and a quick ratio of 1.22.

Analyst Ratings Changes

MASI has been the topic of several research analyst reports. Jefferies Financial Group reissued a “hold” rating and issued a $121.00 price objective (up previously from $107.00) on shares of Masimo in a research note on Tuesday, January 30th. Stifel Nicolaus upgraded Masimo from a “hold” rating to a “buy” rating and lifted their price objective for the company from $148.00 to $170.00 in a report on Monday, April 15th. Piper Sandler upped their price objective on shares of Masimo from $70.00 to $117.00 and gave the stock a “neutral” rating in a research note on Monday, February 26th. BTIG Research raised their target price on shares of Masimo from $145.00 to $166.00 and gave the company a “buy” rating in a research report on Monday, March 25th. Finally, Wells Fargo & Company raised shares of Masimo from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $117.00 to $160.00 in a research report on Monday, March 25th. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Masimo currently has a consensus rating of “Hold” and a consensus price target of $137.43.

Insider Activity at Masimo

In other Masimo news, Director Craig B. Reynolds sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $136.17, for a total value of $5,446,800.00. Following the sale, the director now owns 7,406 shares in the company, valued at approximately $1,008,475.02. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 9.70% of the stock is owned by company insiders.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.